TB R&D Update: New treatment strategy using Bedaquiline in combination with heart medication, Verapamil

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model‘ was recently published in Antimicrobial Agents and Chemotherapy.

Although Bedaquiline is an effective anti-tuberculosis agent, it has significant liver and heart toxicity. Supplementing bedaquiline treatment in mice models with verapamil reduced not only the dosage required and thus toxicity, but also the emergence of antibiotic resistance, without sacrificing potency.

Scientists at the Tuberculosis Research Center plan to use this new data to design clinical trials.

Related Links

Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model

Study indicates new strategy to treat tuberculosis

New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency

Additional Links

Sirturo approved for conditional use in European Union to treat MDR-TB in adults

Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

More News
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...